Women's satisfaction with an intravaginal Lactobacillus capsule for the treatment of bacterial vaginosis

Journal of Women's Health

Volumn 15, Issue 9, 2006, Pages 1053-1060

  Marrazzo, Jeanne M ^a,d   Cook, Robert L ^b   Wiesenfeld, Harold C ^b   Murray, Pamela J ^c   Busse, Barbara ^c   Krohn, Marijane ^b   Hillier, Sharon L ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTOBACILLUS CRISPATUS EXTRACT; METRONIDAZOLE; NATURAL PRODUCT; PLACEBO; UNCLASSIFIED DRUG; PROBIOTIC AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; APPLICATION SITE DISCOMFORT; APPLICATION SITE STICKINESS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LACTOBACILLUS; MAJOR CLINICAL STUDY; PATIENT SATISFACTION; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; VAGINA DISCHARGE; VAGINITIS; DIET THERAPY; DOUBLE BLIND PROCEDURE; INTRAVAGINAL DRUG ADMINISTRATION; MICROBIOLOGY; MICROCAPSULE; MULTIVARIATE ANALYSIS; STATISTICS; TREATMENT OUTCOME; WOMEN'S HEALTH;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; CAPSULES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTOBACILLUS; MULTIVARIATE ANALYSIS; PATIENT SATISFACTION; PROBIOTICS; TREATMENT OUTCOME; VAGINOSIS, BACTERIAL; WOMEN'S HEALTH;

EID: 33847698602     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.15.1053     Document Type: Article

References (22)

1. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics-Approaching a definition. Am J Clin Nutr 2001;73:361S.
2. Eschenbach DA, Hillier S, Critchlow C, Stevens C, DeRouen T, Holmes KK. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988;158:819.
3. Hillier S, Holmes KK. Bacterial vaginosis. In: Holmes KK, Sparling PF, Mardh P-A, et al, eds. Sexually transmitted diseases, 3rd ed. New York: McGraw-Hill, 1999:563.
4. Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: A meta-analysis. Am J Obstet Gynecol 2003;189:139.
5. Hillier S, Krohn MA, Watts DH, Wolner-Hanssen P, Eschenbach D. Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis. Obstet Gynecol 1990;76:407.
6. Hillier SL, Lipinski C, Briselden AM, Eschenbach DA. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Obstet Gynecol 1993;81:963.
7. Hawes SE, Hillier SL, Benedetti J, et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis 1996;174:1058.
8. Antonio MA, Hawes SE, Hillier SL. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis 1999;180:1950.
9. Reid G, Charbonneau D, Erb J, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: Randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 2003;35:131.
10. Hillier SL, Wiesenfeld HC, Murray P, Busse B, Krohn MA, Marrazzo JM. A trial of intravaginal Lactobacillus crispatus as an adjunct to metronidazole therapy for treatment of bacterial vaginosis. Infectious Disease Society of Obstetrics and Gynecology Annual Meeting and Research Symposium. Banff, Canada, 2002. IDSOG, Washington, DC.
11. Elias C, Coggins C. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going? J Womens Health Gend Based Med 2001; 10:163.
12. Prashar S, Simons A, Bryant C, Dowell C, Moore KH. Attitudes to vaginal/urethral touching and device placement in women with urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:4.
13. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14.
14. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991;29:297.
15. Sexually transmitted disease treatment guidelines. MMWR 2002;51 (RR-6), page 43.
16. Coetzee N, Blanchard K, Ellertson C, Hoosen AA, Friedland B. Acceptability and feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides. Aids 2001;15:1837.
17. Jones DL, Weiss SM, Malow R, et al. A brief sexual barrier intervention for women living with AIDS: Acceptability, use, and ethnicity. J Urban Health 2001;78:593.
18. Moon MW, Khumalo-Sakutukwa GN, Heiman JE, Mbizvo MT, Padian NS. Vaginal microbicides for HIV/STI prevention in Zimbabwe: What key informants say. J Transcult Nurs 2002;13:19.
19. Joshi S, Joglekar N, Ghate M, et al. Phase I safety and preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low-risk women in Pune, India. Indian J Med Res 2003;117:152.
20. Mantell JE, Myer L, Carballo-Dieguez A, et al. Microbicide acceptability research: Current approaches and future directions. Soc Sci Med 2005;60:319.
21. Koumans EH, Markowitz LE, Hogan V. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: A synthesis of data. Clin Infect Dis 2002;35:S152.
22. Karasz A, Anderson M. The vaginitis monologues: Women's experiences of vaginal complaints in a primary care setting. Soc Sci Med 2003;56:1013.